PAFSC’s 1st Committee to Review 4 Products Including Pfizer’s Toviaz on Oct. 26

The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs will review four products/indications, including Pfizer Japan’s overactive bladder (OAB) treatment Toviaz Tablets 4 mg/8 mg (fesoterodine fumarate), on October 26. Toviaz is a new molecular entity (NME)...read more